Lipoxen Share Discussion Threads

[rkhl] 17/9/2010 14:05

I am still holding because my average is less than 8p, but I may buy some more if this drops below 7p again. I still think the 4th qtr could be a very good one for LPX and I still think we could reach the 20's with the right news. Market timing is hard to get right so I don't usually chop and change my investments all the time. I will only sell out on a fundamentally bad piece of news or when I reach my target price.

[buywell2] 17/9/2010 08:42

When are you buying back in rkhl ?

[rkhl] 17/9/2010 08:22

In my opinion looks like its heading back towards 6p, shame to see it fall so much like this, they should have mentioned that EPO was behind schedule not on the day they get good news from Baxter, if it is 6-8 weeks behind that should mean we should get results in October, so why say before year end, sounds like it could be anytime in the next 6 months. DYOR.

[rkhl] 16/9/2010 14:56

Shame there are yet more delays with the clinical trials I was expecting an announcement re.EPO, looks like it could be as late as early next year. Disappointing. Baxter news is good but a long way off from being commercial.

[drewz] 16/9/2010 11:09

Surprised there isn't more buying this morning on this stage payment news.

Much more to come.

[buywell2] 16/9/2010 09:04

Interesting I see that Scott McGuire was previously involved with the sale of a company to ...... guess who


Scott started his career in banking with Merrill Lynch in New York in 1987. Formerly Scott was a senior manager in global corporate development at National Medical Care (NMC), at the time the world's largest Haemdialysis provider. During his tenure at NMC he assisted in building the international division and completed over 100 haemodialysis clinic transactions.

He played a key role in building NMCs leading UK and European presence. Since 2002 Scott has been a partner at Healthcare Capital Partners, a company that he founded with Stefano Ciampolini. He is also CEO of Lipoxen Plc, a biotechnology company he listed on AIM (ticker symbol LPX) in 2006. Prior to HCP Scott was director (1996-2001) of Arthur Andersen's Healthcare Corporate Finance, a practice he co-founded in 1996. While at Andersen, Scott advised a number of leading dialysis companies including Althin Medical (manufacturer of dialysis products and consumables) on the sale to Baxter (1999) and Total Renal Care (now DaVita) on their European business development initiatives (1997-1999).

[buywell2] 16/9/2010 08:30

Lipoxen's Ties With Baxter Strengthen After US$4 million Deal

Thursday, September 16, 2010 by Ian Lyall

Lipoxen (AIM:LPX) is strengthening its ties with Baxter International (NYSE:BAX) in a US$4 million deal that gives the drugs giant a seat on the board of UK-listed bio-pharmaceutical firm.

Under the renegotiated terms of its agreement, Lipoxen will receive a US$2 million licence fee.

The AIM-listed group is also issuing warrant rights to subscribe to US$2 million of new equity between July next year and June 2015.

But instead of receiving the US$75 million of milestone payments and royalties negotiated in 2005, Lipoxen will get US$71 million. Baxter also gets to appoint a non-executive director to the Lipoxen board.

The agreement covers the PSA Factor-VIII molecule, which treats haemophilia and uses the Lipoxen-developed PolyXen protein drug delivery technology.

Chief executive Scott Maguire said: "The continued support from Baxter of Lipoxen is key to our efforts to commercialise our platform technologies.

"We are very pleased with the ongoing positive preclinical results for the lead PSA-Factor VIII molecule which we are working on with Baxter."

Lipoxen announced in June its partner is exploring other potential factor replacement therapies in the treatment of haemophilia A and B and for patients with inhibitors.

"We are delighted that our relationship with Baxter continues to evolve and we look forward to leveraging the expertise and success of our Factor VIII for the new candidates under investigation," Maguire added.

"The success of the Baxter partnership and its expansion to further molecules validates the Lipoxen business model where positive pre-clinical and clinical results lead to further partnering opportunities."

While the Factor-VIII agreement with Baxter is important, analysts say the key drivers for Lipoxen remain its improved formulations of insulin and EPO as both are potentially blockbuster drugs.

Maguire expects the phase-II Indian ErepoXen (EPO) trial, managed by Indian partner the Serum Institute of India, to report results by the year-end.

Meanwhile, the phase-II diabetes candidate SuliXen, managed by Russian partner FDA Pharma, compares 'favourably' to market leader Lantus, produced by Sanofi Aventis, Maguire says.

"Our strategy is to get the out-licence areas where big pharmaceutical companies would not want to focus – like India, like Russia," Maguire told Proactive Investors.

"They provide data for these drug candidates and then we are able to out-licence them (in the West) or fund them for development.

"It validates the application of that compound. You are not going to be able to jump into a phase II trials in the US or Europe on the back of this, but it gives us valuable data."

Interesting too is the company's pre-clinical work on multiple sclerosis, cystic fibrosis and its flu vaccine, where an update is expected before the year-end.

In April the group raised £1.2 million, and it later emerged that the senior management were the "cornerstone investors" in the placing.

This underlines the confidence of Maguire and his finance director Colin Hill in the company's prospects.

This confidence is also reflected in a two-part stock option scheme the pair signed up to in June that will see awards at 20p, 40p and 100p a share. The current share price is 8.5p a share.

"We have subscribed to the last two equity placings, "Maguire says. "We bought in the open market.

And there's a stock option programme that goes to 20p, 40p and a pound. So we are committed."

Lipoxen was founded by professor Gregory Gregoriadis and spun out from the School of Pharmacy at the University of London in 1997. It listed on AIM nine years later.

The company targets three specific areas – biological, vaccines and oncology drugs. It has three novel platforms to do this – PolyXen, ImuXen and VesicAll.

However the key focus of the company is the first two platforms.

The PolyXen platform is a versatile protein drug delivery technology. It is essentially based on a polymer of sialic acid which is naturally found in the body.

The polymer is attached to a drug, which generates several positive attributes. As it is a natural substance, it effectively hides the drug from the body's immune system. And it also acts like a tail on the drug, substantially increasing its life once administered.

This means the drug dose frequency required is greatly reduced as the drug is released over a longer time. PolyXen polymers also improve the stability and water solubility.

Rather than focus solely on effectively reengineering drugs on its own, Lipoxen has opted to partner with major pharmaceutical companies such as Baxter which already have blockbuster drugs in the market, but are nearing the end of their patent protection.

Lipoxen offers them a novel solution. By taking an established drug and adding its polymer, the new drug gains all of the improved characteristics of the polymer, and as a reformulation, can reapply for a new patent.

This is clearly an opportunity many pharmaceuticals would not like to miss, and Lipoxen has already signed a string of agreements with large players to develop reengineered version of their own products.

[aim_trader] 16/9/2010 08:27

"Our strategy is to get the out-licence areas where big pharmaceutical companies would not want to focus – like India, like Russia," Maguire told Proactive Investors.

"They provide data for these drug candidates and then we are able to out-licence them (in the West) or fund them for development.

"It validates the application of that compound. You are not going to be able to jump into a phase II trials in the US or Europe on the back of this, but it gives us valuable data."

Interesting too is the company's pre-clinical work on multiple sclerosis, cystic fibrosis and its flu vaccine, where an update is expected before the year-end.


"...Rather than focus solely on effectively reengineering drugs on its own, Lipoxen has opted to partner with major pharmaceutical companies such as Baxter which already have blockbuster drugs in the market, but are nearing the end of their patent protection.

Lipoxen offers them a novel solution. By taking an established drug and adding its polymer, the new drug gains all of the improved characteristics of the polymer, and as a reformulation, can reapply for a new patent.

This is clearly an opportunity many pharmaceuticals would not like to miss, and Lipoxen has already signed a string of agreements with large players to develop reengineered version of their own products."

[buywell2] 16/9/2010 08:26

So the deal is in the bag ..... and there could be more to come

With the selection of the lead candidate now completed and its progression into
pre-clinical development, Lipoxen will continue to work with Baxter to achieve
the remaining US$71 million in additional potential cash milestones payments due
plus royalties.

Baxter has also has been granted the right to nominate a Non-Executive Director
to Lipoxen's Board with such nomination to be made no later than 31 December
2010.

Commenting on the announcement, Scott Maguire, CEO said:

"The continued support from Baxter of Lipoxen is key to our efforts to
commercialise our platform technologies. We are very pleased with the ongoing
positive preclinical results for the lead PSA-Factor VIII molecule which we are
working on with Baxter."

"As announced in June this year, through the investigational studies in process,
Baxter is exploring other potential factor replacement therapies in the
treatment of haemophilia A and B and for patients with inhibitors. We are
delighted that our relationship with one of the world's leading
biopharmaceutical companies continues to evolve and we look forward to
leveraging the expertise and success of our Factor VIII for the new candidates
under investigation. The success of the Baxter partnership and its expansion to
further molecules validates the Lipoxen business model where positive
pre-clinical and clinical results lead to further partnering opportunities."

[buywell2] 16/9/2010 08:21

This is better news

Lipoxen & Baxter Agreement Update



TIDMLPX

RNS Number : 7835S
Lipoxen PLC
16 September 2010

+---------------------------------+---------------------------------+
| For Immediate Release | 16 September 2010 |
| | |
+---------------------------------+---------------------------------+


LIPOXEN & BAXTER AGREEMENT UPDATE

- Lipoxen Receives US$2m License Fee Payment -
- Baxter Issued Warrants to Subscribe for up to US$2m Equity -
- Baxter Selects Lead Polymer Polysialic Acid (PSA)-Factor VIII Candidate -
- Baxter Granted Right to Appoint NED to Lipoxen's Board -

Lipoxen plc (AIM: LPX), ('Lipoxen' or 'the Company') a bio-pharmaceutical
company specialising in the development of high-value differentiated
biologicals, vaccines and siRNA delivery, announces an important transaction
with Baxter International Inc., ("Baxter") a global healthcare company and
Lipoxen's third largest shareholder.

Background:

In August 2005, Lipoxen and Baxter signed a License Agreement with a potential
value of up to US$75 million in cash milestones plus royalties.

The current Transaction has been concluded pursuant to both:

(a) The signing of a License Amendment Agreement, and,
(b) Baxter's selection of a lead PSA-FVIII candidate. PSA-FVIII is a
longer-acting form of a Factor VIII molecule using Lipoxen's PolyXen drug
delivery technology.

Pursuant to the foregoing:

(a) Lipoxen will receive a US$2 million licence fee payment within 20 days of
today's date, being an amount otherwise due at a later date in respect of an
Investigational New Drug (IND) filing as per the original License Agreement of
2005, such current payment being offset against that IND fee, and,
(b) Lipoxen issuing to Baxter warrant rights entitling Baxter, at their sole
option to subscribe for up to US$2m of new equity in Lipoxen from the date
authority to issue sufficient number of shares is available to 30 June 2015 at
an Exercise Price being the Volume Weighted Average Price (VWAP) of Lipoxen's
shares for the 5 trading days up to close of business on September 15th, 2010,
being an Exercise Price of 9.02 pence.

With the selection of the lead candidate now completed and its progression into
pre-clinical development, Lipoxen will continue to work with Baxter to achieve
the remaining US$71 million in additional potential cash milestones payments due
plus royalties.

Baxter has also has been granted the right to nominate a Non-Executive Director
to Lipoxen's Board with such nomination to be made no later than 31 December
2010.

Commenting on the announcement, Scott Maguire, CEO said:

"The continued support from Baxter of Lipoxen is key to our efforts to
commercialise our platform technologies. We are very pleased with the ongoing
positive preclinical results for the lead PSA-Factor VIII molecule which we are
working on with Baxter."

"As announced in June this year, through the investigational studies in process,
Baxter is exploring other potential factor replacement therapies in the
treatment of haemophilia A and B and for patients with inhibitors. We are
delighted that our relationship with one of the world's leading
biopharmaceutical companies continues to evolve and we look forward to
leveraging the expertise and success of our Factor VIII for the new candidates
under investigation. The success of the Baxter partnership and its expansion to
further molecules validates the Lipoxen business model where positive
pre-clinical and clinical results lead to further partnering opportunities."

[aim_trader] 16/9/2010 08:08

Lipoxen's Ties With Baxter Strengthen After US$4 million Deal

[rkhl] 16/9/2010 07:59

Expecting more good news regarding EPO Phase 2 in the next few weeks.

[daicaprice] 16/9/2010 07:56

Marked up, unusual to have a drop before a positive RNS! No leaks even more unusual.

DC

[ohisay] 16/9/2010 07:53

Why don't they just get married and have done with it?

[123asd] 16/9/2010 07:25

Good Lord, is everyone dead here? RNS out!

LIPOXEN & BAXTER AGREEMENT UPDATE

- Lipoxen Receives US$2m License Fee Payment -
- Baxter Issued Warrants to Subscribe for up to US$2m Equity -
- Baxter Selects Lead Polymer Polysialic Acid (PSA)-Factor VIII Candidate -
- Baxter Granted Right to Appoint NED to Lipoxen's Board -

Background:

In August 2005, Lipoxen and Baxter signed a License Agreement with a potential
value of up to US$75 million in cash milestones plus royalties.

The current Transaction has been concluded pursuant to both:

(a) The signing of a License Amendment Agreement, and,
(b) Baxter's selection of a lead PSA-FVIII candidate. PSA-FVIII is a
longer-acting form of a Factor VIII molecule using Lipoxen's PolyXen drug
delivery technology.

Pursuant to the foregoing:

(a) Lipoxen will receive a US$2 million licence fee payment within 20 days of
today's date, being an amount otherwise due at a later date in respect of an
Investigational New Drug (IND) filing as per the original License Agreement of
2005, such current payment being offset against that IND fee, and,
(b) Lipoxen issuing to Baxter warrant rights entitling Baxter, at their sole
option to subscribe for up to US$2m of new equity in Lipoxen from the date
authority to issue sufficient number of shares is available to 30 June 2015 at
an Exercise Price being the Volume Weighted Average Price (VWAP) of Lipoxen's
shares for the 5 trading days up to close of business on September 15th, 2010,
being an Exercise Price of 9.02 pence.

With the selection of the lead candidate now completed and its progression into
pre-clinical development, Lipoxen will continue to work with Baxter to achieve
the remaining US$71 million in additional potential cash milestones payments due
plus royalties.

Baxter has also has been granted the right to nominate a Non-Executive Director
to Lipoxen's Board with such nomination to be made no later than 31 December
2010.

Commenting on the announcement, Scott Maguire, CEO said:

"The continued support from Baxter of Lipoxen is key to our efforts to
commercialise our platform technologies. We are very pleased with the ongoing
positive preclinical results for the lead PSA-Factor VIII molecule which we are
working on with Baxter."

"As announced in June this year, through the investigational studies in process,
Baxter is exploring other potential factor replacement therapies in the
treatment of haemophilia A and B and for patients with inhibitors. We are
delighted that our relationship with one of the world's leading
biopharmaceutical companies continues to evolve and we look forward to
leveraging the expertise and success of our Factor VIII for the new candidates
under investigation. The success of the Baxter partnership and its expansion to
further molecules validates the Lipoxen business model where positive
pre-clinical and clinical results lead to further partnering opportunities."

[rkhl] 14/9/2010 16:18

I thought so the mm's wouldn't be able to hold the price with this constant selling, I think shareholders deserve some clarity, is this EPO trial delayed till the next quarter, according to LPX it should be finished by early Q3, so what is happening, we should be told.

[rkhl] 14/9/2010 13:11

Can't be more than a few days away from news re. EPO P2 which if positive and according to recent reports looking very good we should see a substantial re-rating especially if Baxter have agreed terms.

[ratel] 13/9/2010 08:42

Drewz

Thank you. I bought when it was Acambis -about a £1 I think - and believe I held until the bid. Can't remember much else other than the big profit. Age, I'm afraid. A similar outcome for LPX looks feasible for the patient.

[drewz] 13/9/2010 00:53

It was a company called peptide therapeutics which became Acambis; someone posted this about 9 years ago:


drewz - 30 Nov'01 - 00:26 - 43 of 56 edit

Wish I hadn't sold out in August at 130p. Rotten timing as usual. I only made 250%. Could have been 700% with more patience. Just goes to show - avoid overtrading!!

[ratel] 10/9/2010 11:46

I have recently taken a small position in this company because I like the risk/reward balance. Although I would vehemently deny being superstitious, I have happy memories of a Baxter collaboration with a small UK life sciences company around the year 2000. I cannot recall the name of the company but I made over 100% in less than a year. If Baxter do the necessary with the "rubber stamp", I would think such gains could be exceeded. On the other hand, ......

[pelleeds1980] 10/9/2010 09:21

Creeping up nicely again

[buywell2] 10/9/2010 08:59

Early rise this morning

Previous 9p resistance looks like giving way , 12p next if that is the case

Previous comments re RNS news apply

Baxter Healthcare just need to 'rubber stamp' this stock following their acquisition of over 3% of LPX shares by announcing that Lipoxen have been selected for the factor V111 deal ... 21p resistance could then go the day after

dyor

[buywell2] 09/9/2010 08:57

I read a broker report around a year back that had 40p on this stock based upon the sum of the seperate deals/developments in hand

Chart shows it can be done ....... again, it has been there before , which helps



dyor